TY - JOUR
T1 - Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery
T2 - A randomized, double-blind, placebo-controlled, parallel-group trial
AU - Langford, Richard M.
AU - Joshi, Girish P.
AU - Gan, Tong J.
AU - Mattera, Maria Stoeckl
AU - Chen, Wen Hung
AU - Revicki, Dennis A.
AU - Chen, Connie
AU - Zlateva, Gergana
N1 - Funding Information:
This study was sponsored by Pfizer Inc., New York, NY, USA. The authors would like to thank Raymond Cheung from Pfizer for his detailed review and input. Girish P. Joshi received research grants and honoraria from Pfizer. Connie Chen and Gergana Zlateva are employees and own stock in Pfizer Inc. The other authors have no conflicts of interest that are directly relevant to the content of this study. Editorial support was provided by R. Passmore, PhD, of PAREXEL, and was funded by Pfizer Inc.
PY - 2009
Y1 - 2009
N2 - Background: Multimodal pain therapy including cyclo-oxygenase-2 inhibitors can result in optimal pain management with decreased opioid use and fewer opioid-related adverse events. Patient reported outcomes (PROs) help identify benefits in reduced opioid use and increased pain control. Methods: In this randomized, double-blind trial, patients (n = 1062) undergoing major non-cardiac elective surgery received either parenteral parecoxib for 3 days or placebo then oral valdecoxib or placebo for a total of 10 days, with both arms being allowed additional opioid analgesia. Clinically meaningful opioid-related adverse events were assessed daily using the Opioid- Related Symptom Distress Scale (OR-SDS). Pain severity and interference with function were evaluated daily using the modified Brief Pain Inventory exploratory form (mBPI-e). Additional validation work was undertaken to understand the psychometric properties of the two PROs. Detailed clinical results were reported elsewhere. Results: Patients receiving parecoxib/valdecoxib achieved significantly better pain control and consumed 37% and 28% less opioid medication than the placebo group on day 2 and day 3, respectively. Over the 10-day treatment period, patients receiving parecoxib/valdecoxib consumed 31% less opioid medication. This coincided with significantly fewer (p < 0.0001) OR-SDS clinically meaningful events (CMEs) and lower mBPI-e scores from days 2-10 in the parecoxib/valdecoxib group compared with the placebo group. On day 3, the percentage of patients reporting one, two or three CMEs in the parecoxib/valdecoxib versus placebo group was 11.6% versus 13.0%, 2.3% versus 5.1%, and 0.8% versus 2.3%, respectively. The mean (±standard error) mBPI-e pain severity scores over days 2-10 were 2.47±0.04 for the parecoxib/ valdecoxib group and 3.01±0.04 for the placebo group, and the mean mBPI-e pain interference scores were 1.73 ± 0.04 and 2.19±0.04, respectively. Conclusions: Patients receiving parecoxib/valdecoxib had less pain interference on physical functioning, required less opioid medication and experienced fewer clinically meaningful opioid-related adverse events than patients receiving placebo.
AB - Background: Multimodal pain therapy including cyclo-oxygenase-2 inhibitors can result in optimal pain management with decreased opioid use and fewer opioid-related adverse events. Patient reported outcomes (PROs) help identify benefits in reduced opioid use and increased pain control. Methods: In this randomized, double-blind trial, patients (n = 1062) undergoing major non-cardiac elective surgery received either parenteral parecoxib for 3 days or placebo then oral valdecoxib or placebo for a total of 10 days, with both arms being allowed additional opioid analgesia. Clinically meaningful opioid-related adverse events were assessed daily using the Opioid- Related Symptom Distress Scale (OR-SDS). Pain severity and interference with function were evaluated daily using the modified Brief Pain Inventory exploratory form (mBPI-e). Additional validation work was undertaken to understand the psychometric properties of the two PROs. Detailed clinical results were reported elsewhere. Results: Patients receiving parecoxib/valdecoxib achieved significantly better pain control and consumed 37% and 28% less opioid medication than the placebo group on day 2 and day 3, respectively. Over the 10-day treatment period, patients receiving parecoxib/valdecoxib consumed 31% less opioid medication. This coincided with significantly fewer (p < 0.0001) OR-SDS clinically meaningful events (CMEs) and lower mBPI-e scores from days 2-10 in the parecoxib/valdecoxib group compared with the placebo group. On day 3, the percentage of patients reporting one, two or three CMEs in the parecoxib/valdecoxib versus placebo group was 11.6% versus 13.0%, 2.3% versus 5.1%, and 0.8% versus 2.3%, respectively. The mean (±standard error) mBPI-e pain severity scores over days 2-10 were 2.47±0.04 for the parecoxib/ valdecoxib group and 3.01±0.04 for the placebo group, and the mean mBPI-e pain interference scores were 1.73 ± 0.04 and 2.19±0.04, respectively. Conclusions: Patients receiving parecoxib/valdecoxib had less pain interference on physical functioning, required less opioid medication and experienced fewer clinically meaningful opioid-related adverse events than patients receiving placebo.
UR - http://www.scopus.com/inward/record.url?scp=68949100342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949100342&partnerID=8YFLogxK
U2 - 10.2165/11317570-000000000-00000
DO - 10.2165/11317570-000000000-00000
M3 - Article
C2 - 19663520
AN - SCOPUS:68949100342
SN - 1173-2563
VL - 29
SP - 577
EP - 590
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 9
ER -